The Federal Trade Commission has ordered Illumina to divest cancer screening company Grail, arguing the $8bn acquisition would damage competition in the US market for life saving cancer tests.
The decision reverses an earlier ruling by an administrative law judge in favour of the deal and marks the latest setback to the San Diego-based company’s efforts to diversify into the nascent market for multi-cancer early detection tests.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased